Organon & Co (OGN) stock is soaring 5.16% in pre-market trading on Monday following the release of its impressive third-quarter earnings report. The pharmaceutical company reported adjusted earnings per share of $1.01, surpassing the analysts' expectations of $0.94. Revenue for the quarter also beat estimates, coming in at $1.602 billion compared to the expected $1.575 billion.

The strong quarterly performance was underscored by a significant improvement in profitability metrics. Organon's adjusted EBITDA margin increased to 32.3% from 29.0% in the same quarter last year, primarily due to a 14% reduction in non-GAAP operating expenses. The company's adjusted net income rose to $263 million, up from $226 million in the third quarter of 2024.

However, investors should note that Organon has revised its full-year 2025 revenue guidance downward. The company now expects revenue in the range of $6.2 billion to $6.25 billion, down from its previous forecast of $6.28 billion to $6.38 billion. This adjustment implies a nominal revenue decline between 2.4% and 3.2% for the year. Despite this cautious outlook, the market appears to be focusing on the company's strong quarterly performance and improved profitability, driving the stock's pre-market surge.